WWW.KONF.X-PDF.RU
- , ,
 


Pages:     | 1 |   ...   | 3 | 4 ||

-2 -2b ...

-- [ 5 ] --

. 65. MacroCap SP -2 99,50,5 % ( -).

100 % MCG (50 NaB; 0,01 % polysorbate 80; pH 9,0). 30 % . , -2, .

MacroCap SP - Sephadex G25. :

SE2: 50 NaP; 0,01 % polysorbate 80; pH = 5,5.

-2 99,60,5 %.

2.2.3.5. -2b 66 -2 : (); - ( ) (), - ().

. 66. -2 ; - ; -

, -2 - .

/ : (MDBK) / (VSV).

:

1,5*107 /;

1,3*107 /.

, , .

2.2.4. -2b -2, -2b -2 , . 16.

   

16 , , -2b -2 45020 ( -2b) 60025 ( -2) .

-2b -2 67. ( -2b, -2).

67. -2b -2 , .

2.2.5. -2 -2b . , -2 2 - 8, -2b 34. . -2b 40. 68.

. 68. -2 -2b , : -2 , -2b. 24 2-8.

2.2.6. 2014 -2b , -2 , .

17 -2 -2b

2014. 3 , 30 % .

   

17 , 30 % .

3.

1. ( ; 3 ; 0,5 ; 8,5 .; : 0,1 % 80; : 0,8 ; 6 ; ..: 4,86 /) -2 ( N ). 1,9 , 1,5 , 40 % .

2. , , . 990,5 %, 30 %.

3. -2 ( / 1 2 ; 2 /; : 2-8; 10 .; 9,0 .;

30 %) -2b ( / 1 0,7 ; 14 /;

: ; 80 .; 6,8 .), -2b 4,2 , -2 3 .

4. -2b -2 , : , , , .

5. -2 -2b . , .

6. -2 -2b . -2b ( 120 ) 600 ( 7700 ), -2 ( 180 ) 1000 ( 9900 ).

4.

- 1.

, -2b -2 ( 56882590-22-14 04.12.14, 56882590-23-15 13.01.15).

2. -2b -2b ( N ) ( -2b).

3. (-002542 23.07.2014).

<

5.

1. , -2b -2, , . .

2. , .

6.

1. Abuchowski, A. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol / A. Abuchowski, T. Es, N.

Palczuk, F. Davis // J. Biol. Chem. 1977. Vol. 252. P. 3578 81.

2. Abuchowski, A. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase / A. Abuchowski, J.

McCoy, N. Palczuk, T. Es // J. Biol. Chem. 1977. Vol. 252. P. 358286.

3. Adolf, G. Natural human interferon alpha 2 is O glycosylated / G. Adolf, I.

Kalsner, H. Ahorn // Biochem. J. 1991. Vol. 276. P. 511 518.

4. Ahmed, S. Interferon in the treatment of hairy cell leukemia / S. Ahmed, K. Rai // Best. Pract. Res. Clin. Haematol. 2003. Vol. 16. P. 69 81.

5. Alden, C. L. Handbook of Toxicology Pathology. Urinary system / C. L. Alden, C.H. Frith. New York: Acedemic Press, 1991. P. 339341.

6. Andreoni, M. Primary human Herpesvirus 8 infection in immunocompetent children / M. Andreoni, L. Sarmat, E. Nicastri // J. Am. Med. Ass. 2002. Vol.

287. P. 12951300.

7. Aoki, Y. HIV 1 Tat enhances KSHV infectivity / Y. Aoki, G. Tosato // Blood 2004. Vol. 104. P. 81014.

8. Asmana Ningrum, R. Human interferon alpha 2b: a therapeutic protein for cancer treatment / R. Asmana Ningrum // Scientifica (Cairo). 2014. Vol.

2014. P. 1 8.

9. Bailon, P. PEG modifed biopharmaceuticals / P. Bailon, C. Y. Won // Expert open drug Deliv. 2009. Vol. 6. P. 1 16.

10.Bailon, P. Rational design of a potent, long lasting form of interferon 2a for the treatment of hepatitis C / P. Bailon, A. Palleroni, C. A. Schaffer // Bioconjug.

Chem. 2001. Vol. 12. P. 195 202.

11.Beauchamp, C.O. A new procedure for the synthesis of polyethylene glycol protein adducts, effects on function, receptor recognition and clearance of superoxide dismutase, lactoferrin and 2 macroglobulin / C.O. Beauchamp, S.L.

Gonias, D.P. Menapace // Anal. Biochem. 1983. Vol. 131. P. 25 33.

12.Bekisz, J. Human interferons alpha, beta and omega / J. Bekisz, H. Schmeisser, J.

Hernandez et al // Growth Factors. 2004. Vol. 22. P. 243 51.

13.Ben Bassat, A. Amino terminal processing of proteins / A. Ben Bassat, K.

Bauer // Nature. 1987. Vol. March P. 315 26.

14.Bentley M. D., Fang Z., Harris M. H. Activated polyoxazolines and compositions comprising the same // US002626. 2008.

15.Bentley M. D., Fang Z., Harris M. H. Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation // US023536. 1999.

16.Beranova, M. Effect of cytochrome P 450 inhibition and stimulation on intensity of polyethylene degradation in microsomial fraction of mouse and rat livers / M.

Beranova, R. Wasserbauer, D. Vancurova et al. // Biomaterials. 1990. Vol.

11. P. 52124.

17.Brierley, M. M. IFN a/b receptor interactions to biologic outcomes:

understanding the circuitry / M. M. Brierley, E. Fish // J. Interferon Cytokine Res.

2002. Vol. 22. P. 83545.

18.Buckel, P. Recombinant Protein Drugs Milestones in Drug Therapy / P. Buckel.

Basel: Birkhaeuser, 2001. 207 p.

19.Butt, T. R. SUMO fusion technology for difficult to express proteins / T. R. Butt // Prot. Expr. Purif. 2005. Vol. 43 P. 1 9.

20.Calceti, P. Development and in vivo evaluation of an oral insulin PEG delivery system / P. Calceti, S. Salmaso, G. Walker // Eur. J. Pharm. Sci. 2004. Vol.

22. P. 315 23.

21.Camble, R. Functionally important conserved amino acids in interferon a2 identified with analogues produced from synthetic genes / R. Camble, M. Edge // Biochem. Biophys. Res. Commun. 1986. Vol. 134. P. 1404 11.

22.Cammas, S. Heterobifunctional poly(ethylene oxide): synthesis of alpha methoxy omega amino and alpha hydroxy omega amino PEOs with the same molecular weights / S. Cammas, Y. Nagasaki, K. Kataoka // Bioconjug.

Chem. 1995. Vol. 6. P. 226 30.

23.Cantell, K. Production of interferon in human leukocytes from normal donors with the use of Sendai virus / K. Cantell., S. Hirvonen., H. L. Kauppinen et al. // Methods Enzymol. 1981. Vol. 78. P. 29 38.

24.Carson, M. Ribbons 2.0 / M. Carson // J. Appl. Crystallog. 1991. Vol. 24. P.

958 61.

25.Carter, M.C. Instability of succinyl ester linkages in O2 monosuccinyl cyclic AMP protein conjugates at neutral pH / M.C. Carter, M.E. Meyerhoff // J.

Immunol. Methods. 1985. Vol. 81. P. 245 57.

26.Clark, R. Long acting growth hormones produced by conjugation with polyethylene glycol / R. Clark, K. Olson, G. Fuh // J. Biol. Chem. 1996. Vol.

271. P. 21969 77.

27.Chamow, S. Modification of CD4 immunoadhesin with monomethoxypolyethylene glycol aldehyde via reductive alkylation / S.

Chamow, T. Kogan, M. Venuti // Bioconjugate Chem. 1994. Vol. 5. P. 133

40.

28.Cheng, T. L. Accelerated clearance of polyethylene glycol modified proteins by anti polyethylene glycol IgM / T.L. Cheng, P. Y. Wu, M.F.Wu et al. // Bioconj.

Chem. 1999. Vol. 10. P. 520 28.

29.Cheng, T. L. Monoclonal antibody based quantitation of poly(ethylene glycol) derivatized proteins, liposomes and nanoparticles / T.L. Cheng, C.M. Cheng, B.M. Chen et al. // Bioconj. Chem. 2005. Vol. 16. P. 122531.

30.Cutrone, E. C. Contributions of cloned Type I interferon receptor subunits to differential ligand binding / E. C. Cutrone, J. A. Langer // FEBS Lett. 1997. Vol. 404. P. 197202.

31.David, M. Signal transduction by Type I interferons / M. David // Biotechniques

2002. Vol. 33. P. S58S65.

32.Davis, B. G. Controlled s ite selective glycosylation of proteins by a combined sitedirected mutagenesis and chemical modification approach / R.C. Lloyd, J.B.

Jones // (1998). J. Org. Chem. 1998. Vol. 63. P. 9614 15.

33.Delgado, C. Analytical partitioning of poly(ethylene glycol) modied proteins / C. Delgado, M. Malmsten, J.M. Van Alstine // Journal of Chromatography. 1997. Vol. 692. P. 26372.

34.Deregt, D. Bovine viral diarrhea virus: biotypes and disease / D. Deregt, K. G.

Loewen // Can. Vet. J. 1995. Vol. 36. P. 37178.

35.Diaz, M. Structure of the human type I interferon gene cluster determined from a YAC clone contig / M. Diaz, H. Pomykala, Bohlander S. et al // Genomics. 1994. Vol. 22. P. 54052.

36.Di Bisceglie, A. M. A randomized controlled trial of recombinant alpha interferon therapy for chronic hepatitis B / A. M. Di Bisceglie, N. Bergasa, T.L.

Fong // Am. J. Gastroenterol. 1993. Vol. 88. P. 188792.

37.Dolence E. K., Hu C., Tsang R. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces // US 08/304656. 1997.

38.Domanski, P. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling / P. Domanski, M.

Witte, M. Kellum // J. Biol. Chem. 1995. Vol. 270. P. 2160611.

39.Edwards, C. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF RI) for chronic inflammatory diseases / C. Edwards, S. Martin, J.

Seely // Adv. Drug Deliv. Rev. 2003. Vol. 55. P. 131536.

40.Esposito, P. PEGylation of growth hormone releasing hormone (GRF) analogues / P. Esposito, L. Barbero, P. Caccia // Adv. Drug Del. Rev. 2003. Vol. 55. P. 1279 91.

41.Fasler Kan, E. Interferon activates signal transducers and activators of transcription 5 and 6 in Daudi cells / E. Fasler Kan, A. Pansky, M. Wiederkehr, M. Battegay // Eur. J. Biol. 1998. Vol. 3. P. 514 19.

42.Fee, C. J. Prediction of the Viscosity Radius and the Size Exclusion Chromatography Behavior of PEGylated Proteins / C. J. Fee, J. Van Alstine // Bioconjugate Chemistry. 2004. Vol. 15. P. 1304 13.

43.Fee, C. J. Size comparison between proteins PEGylated with branched and linear poly(ethyleneglycol) molecules / C. J. Fee // Biotechnol. Bioeng. 2007. Vol.

98. P. 72531. 117.

44.Fish, E. Definition of receptor binding domains in interferon alpha / E. Fish // J.

Interferon Res. 1992. Vol. 12. P. 257 66. 34.

45.Foster, G. R. Different Relative Activities of Human Cell Derived Interferon Subtypes: IFN 8 Has Very High Antiviral Potency / G. R. Foster, O.

Rodrigues, F. Ghouze et al. // J. Interferon Cytok. 1996. Vol. 16. P. 1027 33. 16.

46.Foser, S. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon a 2a (PEGASYS) / S. Foser, A.

Schacher, K. A. Weyer, D. Brugger // Protein. Expr. Purif. 2003. Vol. 30. P.

78 87. 72.

47.Friman, S. Hepatic excretion and metabolism of polyethylene glycols and mannitol in the cat / S. Friman, B. Egestad, J. Sjovall et al. // J.

Hepatology. 1993. Vol. 17. P. 4855. 114.

48.Fruijtier Polloth, C. Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products / C. Fruijtier Polloth // Toxicology. 2005. Vol. 214. P. 138. 118.

49.Ghislain, J. Evidence for glycosphingolipid modification of the type 1 IFN receptor / J. Ghislain, C.A. Lingwood, and E.N. Fish // J. Immunol. 1994. Vol. 153. P. 3655 63. 40.

50.Goodbourn, S. Interferons: cellsignaling, immune modulation, antiviral responses and virus countermeasures / S. Goodbourn, L. Didcock and R.E.

Randall // J. Gen. Virol. 2000. Vol. 81. P. 234164. 51.

51.Goodson, R. J. Site directed pegylation of recombinant interleukin 2 at its glycosylation s ite / R. J. Goodson, N.V. Katre // Biotechnology. 1990. Vol. 8.

P. 343 46.98

52.Grace, M. Structural and biologic characterization of pegylated recombinant IFN alpha2b / M. Grace, S. Youngster, G. Gitlin // J. Interferon Cytokine Res. 2001. Vol. 21. P. 110315.

53.Graham, L. Pegaspargase: a review of clinical studies / L. Graham // Adv. Drug.

Deliv. Rev. Vol. 55. P. 12931302.

54.Hardy, M. Characterization of the type I interferon locus and identification of novel genes / M. Hardy, C. Owczarek, L. Jermiin // Genomics. 2004 Vol. 84.

P. 33145.

55.Harris, J. M. Effect of pegylation on pharmaceuticals / J. M. Harris, B. Robert // Nature Reviews Drug Discovery 2003. Vol. 2. P. 214 221. 69.

56.Harris, J. M., Herati, R. M. Preparation and use of polyethylene glycol propionaldehyde // US5252714A. 1993.

57.Harris, J. M. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C / J. M. Harris, A. Kozlowski // J. Controlled Release. 2001. Vol. 72. P. 217 24.

58.Harris J. M., Kozlowski A. Polyethylene glycol and related polymers monosubstituted with propionic or butanolic acids and functional derivatives thereof for biotechnical applications // WO1997003106. 1997.

59.Harris, J. M. Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical / J.

M. Harris. New York: Plenum Publishing, 1992. 388 p.

60.Heathcote, E. Re treatment of chronic hepatitis C with consensus interferon / E.

Heathcote, E. Keeffe, S. Lee // Hepatology. 1998. Vol. 27. P.113643. 142.

61.Heymann, B. Elastic properties of poly(ethylene glycol) studied by molecular dynamics stretching simulations / B. Heymann, H.Grubmuller // Chemical Physics Letters. 1999. Vol. 307. P. 425 32.

62.Hoofnagle, J. Treatment of chronic non A, non B hepatitis with recombinant human alpha Interferon / J. Hoofnagle, K. Mullen, D. Jones // N. Engl. J. Med.

1986. Vol. 315. P. 157578.

63.Humphray, S. DNA sequence and analysis of human chromosome 9 / S.

Humphray, J. K. Oliver, A. R. Hunt et al // Nature. 2004. Vol. 429. P. 369 74.

64.Hu, R. Human IFN Protein Engineering: The Amino Ac id Residues at Positions 86 and 90 Are Important for Antiproliferative Activity / R. Hu, J.

Bekisz, H. Schmeisser // The J. of Immun. 2001. Vol. 167. P. 1482 89.

65.Inada, Y. Application of PEG enzyme and magnetite PEG enzyme conjugates for biotechnological processes / Y. Inada, K. Takahashi, T. Yoshimoto et al. // Trends in Biotechnology. 1988. Vol. 6. P. 131 34.

66.Isaacs, A. Virus interference. I. The interferon / A. Isaacs, J. Lindenmann // Proc.

R. Soc. Lond. B. Biol. Sci. 1957, Vol. 147. P. 258 67.

67.Kadowaki, N. Distinct CpG DNA and polyinosinic polycytidylic acid double stranded RNA, respectively, stimulate CD11ctype 2 dendritic cell precursors and CD11c+dendritic cells to produce type I IFN / N. Kadowaki, S. Antonenko, Y. J. Liu // J. Immunol. Vol. 166. P. 229195.

68.Kalvakolanu, D. V. Alternate interferon signaling pathways / D. V. Kalvakolanu // Pharmacol. Ther. 2003. Vol. 100. P. 129.

]. :

69.Kapos i's Sarcoma [ :

http://www.nlm.nih.gov/medlineplus/kaposissarcoma.html ( 27.06.2005).

70.Katze, M. G. Viruses and interferon: a fight for supremacy / M. G. Katze, Y. He and M.Jr. Gale // Nat. Rev. Immunol. 2002. Vol. 2. P. 67587. 49.

71.Kawai, F. Microbial degradations of polyethers / F. Kawai // Appl. Microbiol.

Biotechnology. 2002. Vol. 58. P. 3038.

72.Kinstler, O.B. Characterization and stability of N terminally PEGylated rhG CSF / O.B. Kinstler, D.N. Brems, S.L. Lauren // Pharm. Res. 1996. Vol. 13. P. 996 1002.

73.Klaus, W. The three dimensional high resolution structure of human interferon

2a determined by heteronuclear NMR spectroscopy in solution / W. Klaus, B.

Gsell, A. Labhardt, B. Wipf // J. Mol. Biol. 1997. Vol. 274. P. 661 75.

74.Kogan, T. P. The synthesis of substituted methoxy poly(ethylene glycol) derivatives suitable for selective protein modification / T.P. Kogan // Synth.

Commun. 1992. Vol. 22. P. 2417 24.

75.Kom, A. Three dimensional model of a human interferon a consensus sequence / A. Korn, D. Rose, E. Fish // J. Interferon Res. 1994. Vol. 14. P. 1 9.

76.Kumaran, J. A structural basis for interferon alpha receptor interactions / J.

Kumaran, L. Wei, L. Kotra et al // FASEB J. 2007, Vol. 21. P. 3288 96.

77.Leader, B. Protein therapeutics: a summary and pharmacological classification / B. Leader, Q. J. Baca, D.E. Golan // Nat. Rev. Drug Discovery. 2008. Vol. 7.

P. 21 39.

78.Lee, D. Preparation and characterization of monopegylated human granulocyte macrophage colonystimulating factor / D. Lee, I. Sharif, S. Kodijalli // J.

Interferon Cytokine Res. 2008. Vol. 28. P. 101.

79.Lee, L. Prolonged circulating lives of single chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds / L.

Lee, C. Conover, C. Shi // Bioconj. Chem. 1999. Vol. 10. P. 973 81.

80.Lee, H. Preparation and characterization of mono PEGylated epidermal growth factor: evaluation of in vitro biologic activity / H. Lee, T. Park // Pharm. Res. 2002. Vol. 19. P. 845 51.

81.Levy, Y. Adenos ine deaminase deficiency with late onset of recurrent infections:

response to treatment with polyethylene glycol modified adenosine deaminase / Y. Levy, M. Hershfield, C. Fernandez Mejia // J. Pediatr. 1988. Vol. 113. P. 31217.

82.Li, Y. Role of p38a map kinase in Type I Interferon signaling / Y. Li, A. Sassano, B. Majchrzak, D.K. Deb // J. Biol. Chem. 2004. Vol. 279. P. 970 79.

83.Lok, A. S. F. A controlled trial of interferon with or without prednisone priming for chronic hepatitis / A. S. F. Lok, P.C. Wu, C.L. Lai, J.Y.N. Lau // Gastroenterology 1992. Vol. 102. P. 209197.

84.Maeda, H. SMANCS and polymer conjugated macromolecular drugs:

advantages in cancer chemotherapy / H. Maeda // Adv. Drug Deliv. Rev. 2001.

Vol. 46. P. 16985.

85.Malmgaard, L. Induction and regulation of IFNs during viral infections / L.

Malmgaard, T. Taniguchi, K. Ogasawara // J. Interferon Cytokine Res. 2004. Vol. 24. P. 43954.

86.Manjula, B. N. Site specific PEGylation of hemoglobin at Cys correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain / B.N. Manjula, A. Tsai, R. Upadhya et al. // Bioconj.

Chem. 2003. Vol. 14. P. 46472.

87.Martinez, A. L., Sherman, M. R., Saifer, M. G. P.,Williams, L. D. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof // WO030617. 2004.

88.Matsushima, A. Modification of E. Coli asparaginase with 2,4 bis(o methoxypolyethylene glycol) 6 chloro s triazine (activated PEG2);

disappearance of binding ability towards anti serum and retention of enzymatic activity / A. Matsushima, H. Nishimura, Y. Ashihara // Chem. Lett. 1980. P.

773 76.

89.Meager, A. The Interferons: Characterization and Application / A. Meager. Weinheim: Wiley Blackwell, 2006. 460 p.

90.Miron, T. A simplified method for the preparation of succinimidyl carbonate polyethylene glycol for coupling to proteins / T. Miron, M. Wilchek // Bioconjug.

Chem. 1993. Vol. 4. P. 568 69.

91.Morpurgo, M. Preparation and characterization of poly(ethylene glycol) vinyl sulfone / M. Morpurgo, F. M. Veronese, D. Kachensky // Bioconjug. Chem. 1996. Vol. 7. P. 363 68.

92.Novick, D. The human interferon alpha/beta receptor: characterization and molecular cloning / D. Novick, B. Cohen, M. Rubinstein // Cell. 1994. Vol.

77. P. 391 400.

93.Nyman, A. Identification of nine interferon alpha subtypes produced by Sendai virus induced human peripheral blood leucocytes / T. Nyman, H. Tolo, J.

Parkkinen // Biochem. J. 1998. Vol. 329. P. 295 302.

94.Oesterhelt, F. Single molecule force spectroscopy by AFM indicates helical structure of poly(ethylene glycol) in water / F. Oesterhelt, M. Rief, H.E. Gaub // New J. Phys. 1999. Vol. 1. P.6.1 6.11.

95.Pasut, G. Protein, peptide and non peptide drug PEGylation for therapeutic application / G. Pasut, A. Guiotto, F. Veronese // Expert Opinion on Therapeutic Patents. 2004. Vol. 14. P. 85994.

96.Pestka, S. Interferons and their actions / S. Pestka, J. Langer, K. Zoon et al // Annu. Rev. Biochem. 1987. Vol. 56. P. 72777.

97. Pestka, S. The human interferon alpha species and hybrid Proteins. / S. Pestka // Semin. Oncol. 1997. Vol. 24. P. 917.

98. Pfeffer, L. M. The short form of the interferon alfa/beta receptor chain 2 acts as a dominant negative for Type I interferon action / L. Pfeffer, L. Basu, S.R. Pfeffer, C.H. Yang // J. Biol. Chem. 1997. Vol. 272. P. 110025.

99. Piquet, G. Set up of large laboratory scale chromatographic separations of poly(ethylene glycol) derivatives of the growth hormone releasing factor 129 analogue / G. Piquet, M. Gatti, L. Barbero // J. Chromatogr. A. 2002. Vol. 944.

P. 141 48.

100. Platanias, L. C. The p38 mitogen activated protein kinase pathway and its role in interferon signaling / L. Platanias // Pharm. Ther. 2003. Vol. 98. P. 129 42.

101. Polyethylene glycols. [ ] / /Who Food Additives Series 14.

:

2014. :

www.inchem.org/documents/jecfa/jecmono/v14je19.htm ( 13.08.2011).

102. Poynard, T. Randomized trial of interferon alfa 2b plus ribavirin versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus / T. Poynard. P. Marcellin, S.S. Lee // Lancet 1998. Vol. 352.

P. 142631.

103. Radhakrishnan, R. Zinc mediated dimer of human interferon alpha 2b revealed by X ray crystallography / R. Radhakrishnan, L. Walter, A. Hruza // Structure. 1996. Vol. 4. P. 145363.

104. Ranucci, E. Synthesis and molecular weight characterization of end functionalized poly(N vinylpyrrolidone) oligomers / E. Ranucci, G. Spagnoli, L.

Sartore, P. Bigotti // Macrom. Chem. Phys. 1995. Vol. 196. P. 763 74.

105. Richter, A. W. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins / A.W.

Richter, E. Akerblom // Int. Arch. Allergy Appl. Immunol. 1983. Vol. 74. P.

121 24.

106. Roberts, M.J. Chemistry for peptide and protein PEGylation / M.J. Roberts, M.D. Bentley, J.M. Harris // Advanced Drug Delivery Reviews. 2002. Vol. 54.

P. 459 76.

107. Russell Harde, D. Reconstitution of a high affinity binding s ite for Type I interferons / D. Russell Harde, H. Pu, M. Betts, R.N. Harkins // J. Biol. Chem. 1995. Vol. 270. P. 2603336.

108. Samuel, C. Antiviral actions of interferons / C. Samuel // Clin. Microbiol. Rev.

2001. Vol. 14. P. 778809.

109. Schiavon, O. Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N acryloylmorpholine) / O. Schiavon, P. Caliceti, P. Ferruti, F.M. Veronese // Farmaco. 2000. Vol. 55. P. 26469.

110. Schlapschy, M. PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins / M. Schlapschy, U. Binder, C. Borger et al //Protein. Eng. Des. Sel. 2013. Vol. 26. P. 489Sen, G. Viruses and interferons / G. Sen // Annu. Rev. Microbiol. 2001. Vol. 55. P. 25581.

112. Siemers, R. Localization of the receptor binding site of IFN alpha 2b / R.

Siemers, L. Hensley, H. Ozer // J. Immunol. 1988. V 141. P. 1550 55.

113. Simmonds, P. Viral heterogeneity of the hepatitis C virus / P. Simmonds // Journal of Hepatology. 1999. Vol. 31. P. 5460.

114. Stark, G. R. How cells respond to interferons / G. R. Stark, I.M. Kerr, B.R.

Williams, R.H. Silverman // Annu. Rev. Biochem. 1998. Vol. 67. P. 227 64.

115. Uze, G. A and b interferons and their receptors and their friends and relations / G. Uze, G. Lutfalla, K.E. Mogensen // J. Interferon Cytokine Res. 1995. Vol.

15. P. 326.

116. Uze, G. Genetic transfer of a functional human interferon alpha receptor into mouse cells : cloning and expression of its cDNA / G. Uze, G. Lutfalla, I. Gresser // Cell. 1990. Vol. 60. P. 225 34.

117. Veronese, F. M. Activation of monomethoxy poly(ethylene glycol) by phenylchloroformate and modification of ribonuclease and superoxide dismutase / F.M. Veronese, R. Largajolli, E. Bossu // Appl. Biochem. Biotechnol. 1985. Vol. 11. P. 141 52.

118. Veronese, F. M. Protein PEGylation, basic science and biological Applications/ F. M. Veronese. Basel: Birkhaeuser, 2009. 289 p.

119. Viscomi, G. C. Human Leukocyte Interferon Alpha: Structure, Pharmacology, and Therapeutic Applications / G. C. Viscomi, M. Grimaldi, E. Palazzini et al. // Med. Res. Rev. 1995. Vol. 15. P. 44578.

120. Von Spect, B. H. Polyvinylpyrrolidone as a soluble carrier of proteins / B. H.

Von Spect, H. Seinfeld, W. Brendel // Physiol. Chem. 1973. Vol. 354. P.

1659 60.

121. Wang, K. Inhibition of neutrophil apoptos is by Type 1 IFN depends on cross talk between phosphoinositol 3 Kinase protein kinase C d, and NF kB signaling pathways / K. Wang, D. Scheel Toellner, S.H. Wong, R. Craddock // J. Immunol.

2003. Vol. 171. P. 103541.

122. Wang, Y. Structural and biological characterization of pegylated recombinant interferon alpha 2b and its therapeutic implications / Y. Wang, S. Youngster, M.

Grace // Advanced Drug Delivery Reviews. 2002. Vol. 54. P. 54770.

123. Webster, R. PEGylated proteins : evaluation of their safety in the absence of definitive metabolism studies / R. Webster, E. Didier, P. Harris et al. // Drug Metab. Dispos. 2007. Vol. 35. P. 916.

124. Weerd, N. Type I interferon receptors: biochemistry and biological functions / N. Weerd, S. Samarajiwa, P. Hertzog // J. Biol. Chem. 2007. Vol. 282. P.

20053 7.

125. Wetzel, R. Assignment of the disulphide bonds of leukocyte interferon / R.

Wetzel // Nature. 1981. Vol. 289. P. 6067.

126. Wetzel, R. Properties of a human alpha interferon purified from E. coli extracts / R. Wetzel, L. Perry, D. Estell // J. Interferon. Res. 1981. Vol. 1. P.

381 90.

127. Wilkinson, M. Interferon gamma produced by mitogen activated T lymphocytes does not directly mediate lymphoproliferation / M. Wilkinson, H.

Leung, I. Crane et al // Eur. J. Immunol. 1985. Vol. 15. P. 404 7.

128. Woghiren, C. Protected thiol polyethylene glycol: a new activated polymer for reversible protein modification / C. Woghiren, B. Sharma, S. Stein // Bioconjug.

Chem. 1993. Vol. 4. P. 314 18.

129. Wong, D. K. Effect of alphainterferon treatment in patients with hepatitis B e antigenpos itive chronic hepatitis B / D. K. Wong, A.M. Cheung, K. ORourke, C.D. Naylor / Ann Intern Med. 1993. Vol. 119. P. 31223.

130. Wylie, D. Carboxyalkylated histidine is a pH dependent product of pegylation with SC PEG / D. Wylie, M. Voloch, S. Lee // Pharmaceutical Research. 2001.

Vol. 18. P. 135460.

131. Yang, B. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats / B. Yang, P. Lum, M. Hayashi // J. Pharm.

Sci. 2004/ Vol. 93. P. 136773.

132. Yeow, W. S. Antiviral activities of interferon subtypes in vivo / W. S. Yeow, C. M. Lawson, M. W. Beilharz // J. Immunol. Vol. 160. P. 293239.

133. Yokoyama, M. Synthesis of poly(ethylene oxide) with heterobifunctional reactive groups at its terminals by an anionic initiator / M. Yokoyama, T. Okano, Y. Sakurai // Bioconjug. Chem. 1992. Vol. 3. P. 275 76.

134. Zalipsky, S. Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins / S. Zalipsky, R. Seltzer, S. Mennon Rudolph // Appl. Biochem. 1992. Vol. 15. P. 100 14.

135. Zalipsky, S. Facile synthesis of hydroxy arboxymethylpolyethylene oxide / S. Zalipsky, G. Barany // J. Bioact. Compat. Polym. 1990. Vol. 5. P.

227 31.

136. Zalipsky, S. Hydrazide derivatives of poly(ethylene glycol) and their bioconjugates / S. Zalipsky. Washington, DC.: ACS Books, 1997. P. 318 340.103

137. Zalipsky, S. Use of functionalized poly(ethylene glycol)s for modification of polypeptides / S. Zalipsky, C. Lee // Biotechnical and Biomedical Applications. 1992. P. 347 70.

138. , .. ( ) / .

. , . . . : Ж , 2005. 368 .

139. . . / . . // . . 2001. 46. . 47.

140. , .. / . . , . . , .. , .. // 2013. 2. . 46 54.

1. -2b 2. -2b 3. -2b 4. -2b 5. -2b 6. -2b



Pages:     | 1 |   ...   | 3 | 4 ||

:

03.02.08 () : ...

- 03.01.06 ( ) , .. 2014 .....

( ) : 03.02.08 ( ) : , .. ...

- - 03.02.08 ( ) : ...

14.01.12- : , . 2015 1. 1.1. 1.1.1. - ...

03.03.04 , , : .. 2015 1....

- 06.02.03 . 2015 .. 6 1. ..19 1.1. ..19 1.2. ...

03.02.03. : , ..., : .., , 2015 1 1.1...

03.02.10 .. 2015 1. 2. ...

03.02.08 ( ) : ...

14.01.12 ( ) : ... .. 2015 1. 1.1. ...

03.02.07 03.03.02 2014 1. 2. 2.1. 12 2.2....

06.02.02 , , , : , , ...

- 25.00.08 ,...

, - 06.01.05 ...

- 03.02.03 ...

14.02.01 : , ...

: 03.03.03 , 2013 8 1. 1.1 ...

14.03.06 , :...

- - 03.02.06 , .. 2015 ...







 
<<     |    
2016 www.konf.x-pdf.ru - - , ,

, .
, , , , 1-2 .